| Stephanie Scott, LVN | |
|
4001 Long Prairie Rd, 140, Flower Mound, TX 75028-1525 | |
| (972) 691-2388 | |
| (972) 691-2766 |
| Full Name | Stephanie Scott |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 4001 Long Prairie Rd, Flower Mound, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225404494 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 307368 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie Scott, LVN 4001 Long Prairie Rd, 140, Flower Mound, TX 75028-1525 Ph: (972) 691-2388 | Stephanie Scott, LVN 4001 Long Prairie Rd, 140, Flower Mound, TX 75028-1525 Ph: (972) 691-2388 |
News Archive
Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB: RMCP), producers of the Rev Vac safety syringe, today announced that it has engaged Cirrus Financial Communications, LLC ("Cirrus") to provide comprehensive financial marketing and investor relations services.
UMass Lowell research projects, ranging from developing new protective gear and sensors to ensure food and water are safe to advanced wireless communications, were recently awarded nearly $12 million in federal funding through the Fiscal Year 20 Defense Appropriations bill.
Patients with a suspected acute ischemic stroke who are taken by emergency medical services (EMS) directly to comprehensive stroke centers rather than the nearest stroke center for care are more likely to receive endovascular therapy, according to research led by investigators at the University of Chicago Medicine, in collaboration with local healthcare and emergency response groups.
New research published in the January 2016 issue of The FASEB Journal suggests that the G-protein-coupled receptor 119 (GPR119) could be a viable treatment target for nonalcoholic fatty liver disease. This receptor has already been identified as a drug target for diabetes and obesity, and this report raises hopes that compounds that target GPR119 for diabetes or obesity might also work for non-alcoholic fatty liver disease.
› Verified 2 days ago